Register for our free email digests:
Chroma Therapeutics Limited
http://www.chromatherapeutics.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Chroma Therapeutics Limited
European Loan Funds F2G's Late-Stage Novel Antifungal
€24m loan from the European Investment Bank with match funding will progress Phase IIb antifungal Olorofim in invasive aspergillosis. CFO Ralf Schmid goes into details with Scrip.
The IO Switch: Making Tumor-Associated Macrophages Work In Our Favor
Emerging Company Profile: Macrophage Pharma is using novel chemistry to deliver therapies directly into tumor-associated macrophages, switching their activity from immunosuppressive to immuno-stimulatory to initiate anti-tumor immune responses.
VC Roundup: 2016 US Investment Ends On A Down Note, But Biopharma Has Second-Best Year
Venture capital investment fell $2.1bn to $7.79bn in 2016, but it was still the second-best year of VC funding for biopharma firms since 2006. Also, Venrock and Correlation closed new health care and technology funds and 10 companies raised $126.8m.
Deals Shaping The Medical Industry, December 2014
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced October-November 2014.
Company Information
- Industry
- Biotechnology
- Other Names / Subsidiaries
-
- CTI BioPharma Corporation